

4/21/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Welcher et al.

Serial No.: Not Yet Assigned

Group Art Unit No.:

Filed: November 28, 2000

Examiner: Not Yet Assigned

For: B7-Like Molecules and Uses Thereof

Docket No.: A-692

JC960 U.S. PRO
09/729264
11/28/00INFORMATION DISCLOSURE STATEMENTAssistant Commissioner for Patents
Washington, DC 20231

Sir:


As a means of complying with the duty of disclosure, applicant submits a "List of References Cited by Applicant" on a modified PTO-1449 form and provides a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Applicant requests consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen, Inc.

Respectfully submitted,



Scott N. Bernstein
Attorney for Applicants
Registration No.: 38,827
Phone: (805) 447-4128
Date: November 28, 2000

Please send all future correspondence to:

US Patent Operations/ SNB
Dept. 430, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE*Express Mail* mail labeling number: EL360689435USDate of Deposit: November 28, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

Lynne Buckbaum
Printed NameLynne Buckbaum
Signature